🚨⭐️ effort led by @jonathanpriantti Yu Fujiwara, MD Maysa Vilbert out now in JCO Precision Oncology on Efficacy of osimertinib in rare EGFR NSCLC. EGFR Resisters. Most comprehensive systematic review to date! Amin Nassar, MD Alessio Cortellini Jair Bar Alfredo Addeo MD Ludimila Cavalcante ascopubs.org/doi/10.1200/PO…

✨Our publication in JCOPO on the efficacy of osimertinib in rare EGFR NSCLC is out! Grateful to collaborate with such a talented team to improve patient care! Jonathan N. Priantti,Yu Fujiwara, MD,Alessio Cortellini, Ludimila Cavalcante and many others! Thank you for the mentorship of Rafeh Naqash, MD! 👏😃

Congratulations Isabella Michelon and Maria Inez Dacoregio!👏 These findings are important in understanding the impact of ADCs in #HER2-low #MBC. Honored to be part of it! Kudos to all the amazing collaborators and mentors Ludimila Cavalcante,Jonathan N. Priantti,Lucas Vian, Paolo Tarantino, Evandro de Azambuja, MD, PhD

So proud to share our work in JCO Precision Oncology 🫁Our meta-analysis highlights the safety and efficacy of #osimertinib in patients with #NSCLC and uncommon #EGFR mutations. I’m really glad and honored to have this amazing international collaboration with this dream team.

1/ I’m thrilled to share our study, “Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies,” now published in JCO Global Oncology ! 🔗 ascopubs.org/doi/full/10.12… This study reflects the dedication and teamwork of everyone involved.

Safety and Efficacy of Osimertinib in Patients With NSCLC and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. brnw.ch/21wP8Hg Rafeh Naqash, MD #LungCancer #NSCLC

Always an inspiration to hear Dr Stephanie Goff present on #TILs. We need to stop thinking about this as palliative therapy! TILs have the potential to CURE- complete responders from National Cancer Institute with 10 year melanoma-specific survival of 96%. Unmodified TILs are just a starting

From Rio de Janeiro to Boston, Cardiff to Kaliningrad, Recife to Madrid – this publication is a testament to the global connections made possible by the #metamasters. Yasmin Mesquita led a study published in the prestigious ‘Journal of the European Academy of Dermatology and

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/39574495/ ✍️Maysa Vilbert Paolo Tarantino Evandro de Azambuja, MD, PhD Ludimila Cavalcante #ADCs #HER2low

JCO Oncology Practice Thanks to this team: Seth Wander Maryam Lustberg MD, MPH, FASCO Laura Testa Renata Colombo Bonadio, MD Maysa Vilbert Ming Wang_CWRU Daxuan Deng

Top of the irAE to you this Monday! 2 ASPirE events to kick off 2025: ASPirE Annual Meeting 2/28 - 3/1: in person think tank graciously hosted by Afreen Shariff, MD Duke Department of Medicine ASPirE Webinar 3/10: Launch of our Tumor Board series hosted by Yinghong Mimi Wang MD Anderson Cancer Center

New in Cancer Treatment Reviews! This updated meta-analysis continues to support the activity of T-DXd in patients with CNS involvement from HER2-positive #breastcancer. Ludimila Cavalcante Maysa Vilbert Anwaar Saeed 🔗cancertreatmentreviews.com/article/S0305-…

Check out poster board E23 🇧🇷 at #GU25 ASCO We evaluated the incidence of skin reaction in EV mono in clinical trials and real-world data 📊 Incidence rate of all-grade skin reactions was 50% and about 10% in grade 3 or higher Maysa Vilbert Isabella Michelon Ana Paula Garcia Cardoso

It’s a wrap for ASPirE ‘25! In medicine we continually see new challenges, face deadly obstacles, and wake up the next day to do it again. Sometimes in light. Sometimes dark. We give each other strength. Keep going fam. Keep going dear patients. Medicine perseveres. Love, ASPirE

Its a wrap! It was a pleasure to host my colleagues and friends around the country for the 2nd #ASPIRE2025 and 3rd #NICT2025 meeting 25 speakers 38 organizations 15 specialties One place Duke Cancer Duke Cancer Network One mission- #irAE

Awesome job Afreen Shariff, MD Pauline Funchain in bringing us all together at the Duke #ASPIRE25 meeting ! Next year to be held at MD Anderson Cancer Center !

Thank you OncoDaily! Honored to be on the ballot for the 2025 IASLC Board of Directors and look forward to the opportunity to expand optimal lung cancer care and clinical trials on a global scale. Suresh S. Ramalingam, MD, FASCO IASLC Winship Cancer Institute of Emory University

Check out this IRAE chapter in the #ASCO25 education book! Come attend the session on May 30th details ⬇️

Happening now at #ASCO25! Come check out my poster at Board #67 in Hall A — would love to connect and discuss our findings! 🧬🩺 #oncology #cancerresearch #NSIGC #immunotherapy #irAE ASPIRE Community of Practice

🚀 More #irAE highlights forthcoming from #ASCO25 and ASCO’s #ASPIRE Community of Practice 🆕 go-to hub for clinicians addressing immune-related toxicities! 🌟 FREE access for non-oncologists (for a limited time), expert discussion + content docs.google.com/forms/d/1zfl_a…